Drug Drug interaction studies in preclinical stage, reduces unexpected adverse events rate in clinical trails

David Temporal | BD Department
26 October 2021

Drug-drug interactions are the most common cause of adverse events during clinical stages in polymedicated patients. Alterations in drugs’ metabolism due to unexpected molecular interactions affect significantly compounds’ pharmacokinetics.

The scientific community agrees that two of the main concerns of drug-drug interactions are (a) the increase of active principles in certain tissues that can reach toxicological levels, and (b) metabolism alterations that reduce the expected mechanism of action.

In pharmacological terms, optimal excretion routes are required to prevent these adverse events. Uptake transmembrane receptors, which are mainly expressed in hepatocytes and kidney epithelial cells, have an essential function regulating the elimination of compounds from the blood to the bile and urine.

OCT2 and MATE1 receptors are relevant membrane-bound transport proteins that regulate the renal and hepatic excretion of drugs in synergy with other receptors, such as MATE-2K. When a xenobiotic inhibits the OCT2 and/or MATE1 transporter, drugs excretion entails a significant metabolic increase in the inner cell concentration, thus enhancing the possibility of adverse events due to a possible compound’s toxicity.

Main regulatory agencies recommend in their guidelines investigating uptake receptor interactions for novel compounds during preclinical trials. In vitro models with genetically modified cell lines that overexpress these transporters allow to determine transporter-mediated transmembrane protein interactions, which helps to depict the novel compounds pharmacokinetic profile and obtain additional assessment whether the sponsor should conduct in vivo studies in later stages.

Inhibitions studies Substrate studies
MATE1 Transporter Obligatory Recommended Obligatory Recommended Obligatory* Recommended
 OCT2  Transporter Obligatory Obligatory Obligatory Recommended Obligatory* Obligatory*


ReadyCell developed PreadyTake in vitro kits based on transfected HEK 293 cells to assess receptor-mediated interactions with relevant uptake transmembrane receptors that study renal pharmacology.

  • PreadyTake MATE1, seeded with HEK293 cells transfected with SLC47A1 gene, overexpressing MATE1 receptor.
  • PreadyTake OCT2, 96 wells kit with transfected HEK293 cells, overexpressing OCT2 receptor.

PreadyTake kits are shipped worldwide thanks to ReadyCell’s patented Shipping Medium biotechnology, which assures HEK293 cells viability up to 5 days.

For additional scientific discussion related to drug-drug interaction in preclinical stages, contact our scientists at reagents@readycell.com

Related posts

Select the right well system for your research: A comprehensive guide.

Select the right well system for your research: A comprehensive guide.

In preclinical research, the choice of the appropriate well system format – whether it’s a transwell, non-transwell, or individual transwell – can significantly impact the outcome of experiments. Selecting the correct plate is crucial to working with permeability, toxicity, drug screening, or other assays.

Presenting the last advances in transporters in Germany

Presenting the last advances in transporters in Germany

On May 15-17, the 22nd Barrier- and Transporter- days took place in Germany. At the event, Jonatan Cucala, R&D researcher at ReadyCell, presented a poster entitled “PreadyTake, an in vitro ready-to-use cell-based model to evaluate potential drug-transporter interactions.”